Evox Therapeutics Appoints Douglas Treco, Ph.D., to Board of Directors
Evox Therapeutics Ltd (“Evox” or the “Company”), a biotechnology company developing innovative therapies for rare, genetically driven neurodegenerative diseases using a next-generation gene editing modality, today announced the appointment of Douglas Treco, Ph.D., as a Non-Executive Director of the Company’s Board of Directors.
